News | Heart Failure | May 18, 2018

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Subgroup analysis of FIX-HF-5 study found CCM therapy with Optimizer device significantly improved exercise tolerance and quality of life for one subset of heart failure patients

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics


May 18, 2018 — In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise tolerance (ET) and quality of life (QoL) for patients with persistent symptomatic heart failure and an ejection fraction between 25 and 45 percent.  Results of the prospective FIX-HF-5C Study were presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston.                     

CCM therapy for patients with persistent symptomatic heart failure (NYHA Class III and IV) consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. The objective of the prospective FIX-HF-5C study was to confirm a subgroup analysis of a prior study (FIX- HF-5) showing that CCM significantly improved ET and QoL in the target patient group.

One hundred and sixty patients were randomized to continued medical therapy alone (Control) or to continued medical therapy plus CCM delivered by Impulse Dynamics’ Optimizer system (Treatment) for 24 weeks. All patients had NYHA III or IV symptoms despite guideline recommended therapy, QRS duration <130ms and LVEF 25-45 percent. Peak VO2 (pVO2, primary endpoint), Minnesota Living with Heart Failure Questionnaire (MLWHFQ), NYHA and six-minute hall walk (6MHW) test were measured at baseline, 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis, with 30 percent borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events, with a prespecified lower bound of 70 percent.

The difference in pVO2 between Treatment and Control was 0.836 mlO2/kg/min with a 95 percent Bayesian credible interval of (0.123, 1.552 mlO2/kg/min), satisfying the primary endpoint. MLWHFQ (p<0.001), NYHA (p<0.001) and 6MHW (p=0.01) were all better in Treatment vs Control. There were seven device-related events, yielding a lower bound of 80% of patients free of events.

For more information: www.hrssessions.org

Related HRS Content

Heart Rhythm 2018 Late-breaking Studies

Long-Term Data Demonstrate Safety, Efficacy of Optimizer System


Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now